Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pramipexole

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

- PMLiVE

Boehringer talks More Health on new blog

Pharma company's US team looks to connect with 'social entrepreneurs'

- PMLiVE

Boehringer takes leukaemia drug volasertib into phase III

Shows positive results in a difficult-to-treat patient population

- PMLiVE

FDA approves Exelixis’ Cometriq for rare thyroid cancer

Genomics-based discovery company also submits the drug to EU regulators

- PMLiVE

Boehringer launches COPD awareness drive in Japan

Social media campaign will target male smokers’ wives and daughters

- PMLiVE

Acadia shares increase as pimavanserin clears phase III trial

Demonstrated to reduce psychotic symptoms

- PMLiVE

Ranbaxy recalls generic Lipitor in US

Several batches withdrawn after some products found to contain small particles of glass

- PMLiVE

Boehringer launches online education portal for hepatitis C

Comes as company moves its interferon-free hep C regimen into phase III

Novartis building

Canada and Switzerland lift Novartis flu vaccines ban

Independent tests confirm safety following contamination fears

- PMLiVE

Will Boehringer succeed with Syrum?

Time will tell if Boehringer’s bold ambitions for its Facebook game can be fulfilled

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links